Apollo Hospitals Enterprise Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- ✓Excellent return on equity (ROE 22.1%)
- ✓Efficient capital deployment (ROCE 17.9%)
Concerns
- ✗High premium to book value (P/B 13.6x)
- ✗Trading near 52-week high (₹9,009)
Today's Price Action
The stock closed at ₹8,925, unchanged from the previous session. Trading volume registered 2,00,141 shares, exactly matching the 20‑day average, indicating a neutral participation level and no abnormal buying‑ or selling‑pressure on the day.
Valuation Snapshot
The price‑to‑earnings multiple stands at 64.9, considerably higher than the “not applicable” figure for the broader healthcare sector, implying a premium valuation relative to earnings. A return on equity of 22.1% reflects strong profitability and efficient capital utilisation.
Key Levels to Watch
The current price sits near the upper end of the 52‑week range (₹6,680‑₹9,009), leaving limited upside room before encountering historic resistance. Open‑interest data for nearby option strikes shows heightened interest around the ₹9,200‑₹9,400 band, which may act as a short‑term ceiling if the price attempts to breach the 52‑week high.
Chart Pattern
Two bullish engulfing candles appeared on the daily chart—one eight days ago and another two days ago—while an evening‑star formation occurred nine days earlier. These candlesticks suggest a recent contest between upward and downward momentum, with the engulfing patterns typically indicating a shift in short‑term dominance, and the evening‑star often signalling a pause or potential
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
| MAXHEALTH Max Healthcare Institute Limited | ₹1,080 | ₹1.1L Cr | 71.5 | 9.82 | 14.7 | 14.7 | 0.33 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
APOLLOHOSP · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 29.33% | 29.33% | 29.33% | 29.33% | 29.33% | 29.34% |
| FII | 46.25% | 45.63% | 43.92% | 45.37% | 45.27% | 42.74% |
| DII | 18.87% | 19.55% | 21.13% | 19.94% | 19.97% | 22.29% |
| Public | 5.32% | 5.26% | 5.38% | 5.12% | 5.21% | 5.41% |
| Govt | 0.23% | 0.23% | 0.23% | 0.23% | 0.23% | 0.23% |
Corporate Events
To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters
To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters
Interim Dividend - Rs 10 Per Sh
Dividend - Rs 10 Per Share
Interim Dividend - Rs 9 Per Share
Record: 14 Feb 2025
Annual General Meeting/Dividend - Rs 10 Per Share
Record: 16 Aug 2024
Interim Dividend - Rs 6 Per Share
Annual General Meeting/Dividend - Rs 9 Per Share
Record: 18 Aug 2023
Latest News
All news →Apollo Hospitals proposes corporate restructuring via scheme of arrangement
*Apollo Hospitals proposes corporate restructuring via scheme of arrangement.* The move aims to streamline operations and improve governance. No financial impact or change in shareholding pattern is expected. Regulatory approvals will be sought in due course. 📊 *STOCKS:* APOLLOHOSP | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #Restructuring
Apollo Hospitals proposes scheme of arrangement for corporate restructuring
*Apollo Hospitals proposes a scheme of arrangement for corporate restructuring.* Additional details have been disclosed under the NSE corporate filing. The move aims to streamline operations and improve governance. No financial impact disclosed yet. 📊 *STOCKS:* APOLLOHOSP | 🏢 *SECTOR:* Healthcare | #MEDIUMIMPACT #Restructuring
Zydus ties up with Apollo to expand cancer test access
*Zydus ties up with Apollo to expand cancer test access* — Zydus Lifesciences has signed an MoU with Apollo Hospitals to expand access to the Shield Multi-Cancer Detection (MCD) test across India. The collaboration aims to enhance early cancer screening in tier-2 and tier-3 cities. The test is currently available in **15 cities** and plans to scale to **50 cities** by 2027. 📊 *STOCKS:* ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Partnership
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹6.5K Cr ▲2.7% | ₹6.3K Cr ▲7.9% | ₹5.8K Cr ▲4.5% | ₹5.6K Cr ▲1.2% | ₹5.5K Cr ▼1.1% | ₹5.6K Cr ▲9.9% | ₹5.1K Cr ▲2.9% | ₹4.9K Cr |
| Op. Profit | ₹965 Cr ▲2.6% | ₹941 Cr ▲10.4% | ₹852 Cr ▲10.6% | ₹770 Cr ▲1.0% | ₹762 Cr ▼6.6% | ₹816 Cr ▲20.9% | ₹675 Cr ▲5.5% | ₹640 Cr |
| OPM | 15.0% ▲0.0% | 15.0% ▲0.0% | 15.0% ▲7.1% | 14.0% ▲0.0% | 14.0% ▼6.7% | 15.0% ▲15.4% | 13.0% ▲0.0% | 13.0% |
| Net Profit | ₹516 Cr ▲4.5% | ₹494 Cr ▲12.0% | ₹441 Cr ▲6.5% | ₹414 Cr ▲9.2% | ₹379 Cr ▼4.3% | ₹396 Cr ▲25.3% | ₹316 Cr ▲22.5% | ₹258 Cr |
| EPS (₹) | 34.93 ▲5.2% | 33.19 ▲10.3% | 30.1 ▲11.1% | 27.1 ▲4.7% | 25.89 ▼1.7% | 26.34 ▲24.1% | 21.23 ▲20.3% | 17.65 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹25.2K Cr ▲15.8% | ₹21.8K Cr ▲14.4% | ₹19.1K Cr ▲14.7% | ₹16.6K Cr ▲13.3% | ₹14.7K Cr ▲38.9% | ₹10.6K Cr ▼6.1% | ₹11.2K Cr ▲16.9% | ₹9.6K Cr ▲16.7% | ₹8.2K Cr ▲13.6% | ₹7.3K Cr |
| Expenses | ₹21.5K Cr ▲14.4% | ₹18.8K Cr ▲12.6% | ₹16.7K Cr ▲14.6% | ₹14.5K Cr ▲16.6% | ₹12.5K Cr ▲32.4% | ₹9.4K Cr ▼2.4% | ₹9.7K Cr ▲13.0% | ₹8.5K Cr ▲14.9% | ₹7.4K Cr ▲14.1% | ₹6.5K Cr |
| Op. Profit | ₹3.8K Cr ▲24.3% | ₹3.0K Cr ▲26.7% | ₹2.4K Cr ▲15.9% | ₹2.1K Cr ▼5.7% | ₹2.2K Cr ▲92.0% | ₹1.1K Cr ▼28.3% | ₹1.6K Cr ▲48.7% | ₹1.1K Cr ▲33.6% | ₹801 Cr ▲9.1% | ₹734 Cr |
| OPM | 15.0% ▲7.1% | 14.0% ▲7.7% | 13.0% ▲8.3% | 12.0% ▼20.0% | 15.0% ▲36.4% | 11.0% ▼21.4% | 14.0% ▲27.3% | 11.0% ▲10.0% | 10.0% ▲0.0% | 10.0% |
| Other Income | ₹217 Cr ▼2.3% | ₹222 Cr ▲80.5% | ₹123 Cr ▲64.0% | ₹75 Cr ▼79.6% | ₹368 Cr ▲257.3% | ₹103 Cr ▼53.6% | ₹222 Cr ▲753.8% | ₹26 Cr ▲8.3% | ₹24 Cr ▼60.0% | ₹60 Cr |
| Interest | ₹450 Cr ▼1.7% | ₹458 Cr ▲2.0% | ₹449 Cr ▲17.8% | ₹381 Cr ▲0.5% | ₹379 Cr ▼15.6% | ₹449 Cr ▼15.8% | ₹533 Cr ▲63.0% | ₹327 Cr ▲10.8% | ₹295 Cr ▲14.8% | ₹257 Cr |
| Depreciation | ₹876 Cr ▲15.6% | ₹758 Cr ▲10.3% | ₹687 Cr ▲11.7% | ₹615 Cr ▲2.3% | ₹601 Cr ▲4.9% | ₹573 Cr ▼7.6% | ₹620 Cr ▲56.6% | ₹396 Cr ▲10.3% | ₹359 Cr ▲14.3% | ₹314 Cr |
| PBT | ₹2.7K Cr ▲30.5% | ₹2.0K Cr ▲47.8% | ₹1.4K Cr ▲20.6% | ₹1.1K Cr ▼27.5% | ₹1.6K Cr ▲614.0% | ₹221 Cr ▼66.5% | ₹660 Cr ▲76.9% | ₹373 Cr ▲118.1% | ₹171 Cr ▼23.0% | ₹222 Cr |
| Tax % | 25.0% ▼3.8% | 26.0% ▼18.8% | 32.0% ▲45.5% | 22.0% ▼26.7% | 30.0% ▼21.1% | 38.0% ▲11.8% | 34.0% ▼27.7% | 47.0% ▼27.7% | 65.0% ▲58.5% | 41.0% |
| Net Profit | ₹2.0K Cr ▲33.1% | ₹1.5K Cr ▲61.0% | ₹935 Cr ▲10.8% | ₹844 Cr ▼23.8% | ₹1.1K Cr ▲708.8% | ₹137 Cr ▼68.3% | ₹432 Cr ▲116.0% | ₹200 Cr ▲233.3% | ₹60 Cr ▼54.2% | ₹131 Cr |
| EPS (₹) | 135.04 ▲34.3% | 100.56 ▲60.9% | 62.5 ▲9.7% | 56.97 ▼22.4% | 73.42 ▲601.9% | 10.46 ▼68.0% | 32.7 ▲92.8% | 16.96 ▲100.9% | 8.44 ▼46.9% | 15.88 |
| Div Payout | 15.0% ▲15.4% | 13.0% ▼50.0% | 26.0% ▲0.0% | 26.0% ▲62.5% | 16.0% ▼44.8% | 29.0% ▲61.1% | 18.0% ▼48.6% | 35.0% ▼40.7% | 59.0% ▲55.3% | 38.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | ||||||||||
| Equity Capital | ₹72 Cr ▲0.0% | ₹72 Cr ▲0.0% | ₹72 Cr ▲0.0% | ₹72 Cr ▲0.0% | ₹72 Cr ▲0.0% | ₹72 Cr ▲2.9% | ₹70 Cr ▲0.0% | ₹70 Cr ▲0.0% | ₹70 Cr ▲0.0% | ₹70 Cr |
| Reserves | ₹9.0K Cr ▲10.8% | ₹8.1K Cr ▲18.6% | ₹6.9K Cr ▲12.0% | ₹6.1K Cr ▲10.4% | ₹5.6K Cr ▲22.5% | ₹4.5K Cr ▲38.6% | ₹3.3K Cr ▲0.2% | ₹3.3K Cr ▲2.6% | ₹3.2K Cr ▼1.9% | ₹3.2K Cr |
| Borrowings | ₹8.0K Cr ▲1.6% | ₹7.9K Cr ▲47.5% | ₹5.3K Cr ▲23.1% | ₹4.3K Cr ▲6.5% | ₹4.1K Cr ▼2.2% | ₹4.2K Cr ▲15.7% | ₹3.6K Cr ▼2.1% | ₹3.7K Cr ▲7.2% | ₹3.4K Cr ▲9.7% | ₹3.1K Cr |
| Other Liabilities | ₹4.9K Cr ▲6.6% | ₹4.6K Cr ▲2.1% | ₹4.5K Cr ▲15.1% | ₹3.9K Cr ▲8.9% | ₹3.6K Cr ▲35.8% | ₹2.6K Cr ▼39.6% | ₹4.4K Cr ▲101.7% | ₹2.2K Cr ▲12.6% | ₹1.9K Cr ▲15.1% | ₹1.7K Cr |
| Total Liabilities | ₹21.9K Cr ▲6.3% | ₹20.6K Cr ▲23.3% | ₹16.7K Cr ▲16.1% | ₹14.4K Cr ▲8.7% | ₹13.3K Cr ▲16.4% | ₹11.4K Cr ▲0.9% | ₹11.3K Cr ▲23.2% | ₹9.2K Cr ▲6.6% | ₹8.6K Cr ▲6.1% | ₹8.1K Cr |
| Assets | ||||||||||
| Fixed Assets | ₹11.3K Cr ▲2.5% | ₹11.0K Cr ▲13.7% | ₹9.7K Cr ▲13.4% | ₹8.5K Cr ▲2.7% | ₹8.3K Cr ▲22.4% | ₹6.8K Cr ▼8.8% | ₹7.4K Cr ▲49.2% | ₹5.0K Cr ▲4.4% | ₹4.8K Cr ▲4.0% | ₹4.6K Cr |
| CWIP | ₹1.0K Cr ▲11.4% | ₹921 Cr ▲5.5% | ₹873 Cr ▲43.1% | ₹610 Cr ▲1226.1% | ₹46 Cr ▼80.3% | ₹234 Cr ▼0.8% | ₹236 Cr ▼71.3% | ₹822 Cr ▲15.4% | ₹712 Cr ▲105.2% | ₹347 Cr |
| Investments | ₹3.0K Cr ▲20.9% | ₹2.5K Cr ▲152.2% | ₹986 Cr ▲71.8% | ₹574 Cr ▼29.7% | ₹816 Cr ▼39.2% | ₹1.3K Cr ▲209.4% | ₹434 Cr ▼6.1% | ₹462 Cr ▲31.3% | ₹352 Cr ▼13.3% | ₹406 Cr |
| Other Assets | ₹6.7K Cr ▲6.5% | ₹6.2K Cr ▲19.7% | ₹5.2K Cr ▲10.8% | ₹4.7K Cr ▲14.8% | ₹4.1K Cr ▲35.1% | ₹3.0K Cr ▼4.7% | ₹3.2K Cr ▲9.9% | ₹2.9K Cr ▲5.1% | ₹2.8K Cr ▲0.0% | ₹2.8K Cr |
| Total Assets | ₹21.9K Cr ▲6.3% | ₹20.6K Cr ▲23.3% | ₹16.7K Cr ▲16.1% | ₹14.4K Cr ▲8.7% | ₹13.3K Cr ▲16.4% | ₹11.4K Cr ▲0.9% | ₹11.3K Cr ▲23.2% | ₹9.2K Cr ▲6.6% | ₹8.6K Cr ▲6.1% | ₹8.1K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹2.1K Cr ▲11.3% | ₹1.9K Cr ▲39.4% | ₹1.4K Cr ▼18.8% | ₹1.7K Cr ▲34.1% | ₹1.3K Cr ▼2.2% | ₹1.3K Cr ▲42.9% | ₹905 Cr ▲68.5% | ₹537 Cr ▼13.8% | ₹623 Cr ▲4.4% | ₹597 Cr |
| Investing CF | ₹-3.4K Cr ▼120.0% | ₹-1.5K Cr ▼79.3% | ₹-857 Cr ▼14.7% | ₹-747 Cr ▲15.1% | ₹-880 Cr ▼204.5% | ₹-289 Cr ▲59.4% | ₹-711 Cr ▼75.6% | ₹-405 Cr ▲64.8% | ₹-1.2K Cr ▼29.7% | ₹-888 Cr |
| Financing CF | ₹1.3K Cr ▲523.5% | ₹-311 Cr ▲50.9% | ₹-633 Cr ▲20.1% | ₹-792 Cr ▼132.9% | ₹-340 Cr ▲62.6% | ₹-910 Cr ▼323.3% | ₹-215 Cr ▼99.1% | ₹-108 Cr ▼122.6% | ₹477 Cr ▲44.5% | ₹330 Cr |
| Net Cash Flow | ₹73 Cr ▲1.4% | ₹72 Cr ▲163.7% | ₹-113 Cr ▼171.5% | ₹158 Cr ▲259.1% | ₹44 Cr ▼53.2% | ₹94 Cr ▲570.0% | ₹-20 Cr ▼183.3% | ₹24 Cr ▲146.2% | ₹-52 Cr ▼233.3% | ₹39 Cr |
| Free Cash Flow | ₹439 Cr ▼44.1% | ₹785 Cr ▲211.5% | ₹252 Cr ▼75.9% | ₹1.0K Cr ▲6.1% | ₹984 Cr ▲25.8% | ₹782 Cr ▲235.6% | ₹233 Cr ▲377.4% | ₹-84 Cr ▼82.6% | ₹-46 Cr ▲88.3% | ₹-393 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 51d ▲6.3% | 48d ▼2.0% | 49d ▲11.4% | 44d ▼4.3% | 46d ▲39.4% | 33d ▼15.4% | 39d ▲5.4% | 37d ▼2.6% | 38d ▲5.6% | 36d |
| Inventory Days | 16d ▼5.9% | 17d ▲0.0% | 17d ▼19.0% | 21d ▲31.3% | 16d ▼67.3% | 49d ▲6.5% | 46d ▼9.8% | 51d ▲8.5% | 47d ▼4.1% | 49d |
| Days Payable | 72d ▼18.2% | 88d ▲7.3% | 82d ▲3.8% | 79d ▲6.8% | 74d ▲23.3% | 60d ▲7.1% | 56d ▲1.8% | 55d ▲7.8% | 51d ▼22.7% | 66d |
| Cash Conv. Cycle | -6d ▲73.9% | -23d ▼43.8% | -16d ▼14.3% | -14d ▼16.7% | -12d ▼154.5% | 22d ▼24.1% | 29d ▼12.1% | 33d ▼2.9% | 34d ▲78.9% | 19d |
| Working Capital Days | -6d ▲68.4% | -19d ▼1800.0% | -1d ▼120.0% | 5d ▲225.0% | -4d ▲50.0% | -8d ▼166.7% | -3d ▼137.5% | 8d ▼70.4% | 27d ▲68.8% | 16d |
| ROCE | 17.0% ▲13.3% | 15.0% ▲7.1% | 14.0% ▼17.6% | 17.0% ▲112.5% | 8.0% ▼42.9% | 14.0% ▲40.0% | 10.0% ▲42.9% | 7.0% ▼12.5% | 8.0% ▼11.1% | 9.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Apollo Hospitals Enterprise Limited
Apollo Hospitals was established in 1983 by Dr. Prathap C Reddy, renowned architect of modern healthcare in India. As the nation’s first corporate hospital, Apollo Hospitals is acclaimed for pioneering the private healthcare revolution in the country.
Healthcare · Healthcare Services